P&T Ulcerative
Colitis

MMIT recently held a syndicated, simulated P&T session focused on the approvals of mirikizumab and filgotinib, and the launch of Amjevita (biosimilar Humira).

MMIT’s syndicated P&T Perspectives session provides qualitative and tangible feedback through a simulated P&T session that informs your brand’s strategy and enables you to understand how your product and/or competitor’s product will fare in an actual P&T Committee review.

Learn how you can use P&T Perspectives to:

• See how a simulated large, national multi-state health plan will review new to market entrants through a 90-minute live-streaming session with 15-minute Q&A
• Understand how health plans are running cost analyses on your brand or competitors
• Learn from autonomously developed session material and clinical dossiers to inform brand strategy and messaging